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OBJECTIVES In this study, we determined whether fibrin glue improves cell transplant retention and
survival, reduces infarct expansion, and induces neovasculature formation.
BACKGROUND Current efforts in restoring the myocardium after myocardial infarction (MI) include the
delivery of viable cells to replace necrotic cardiomyocytes. Cellular transplantation techniques
are, however, limited by transplanted cell retention and survival within the ischemic tissue.
METHODS The left coronary artery of rats was occluded for 17 min followed by reperfusion. One week
later, bovine serum albumin (BSA), fibrin glue, skeletal myoblasts in BSA, or skeletal
myoblasts in fibrin glue were injected into the infarcted area of the left ventricle. The animals
were euthanized five weeks after injection, and their hearts were excised, fresh frozen, and
sectioned for histology and immunohistochemistry.
RESULTS After five weeks, the mean area covered by skeletal myoblasts in fibrin glue was significantly
greater than the area covered by myoblasts injected in BSA. Myoblasts within the infarct were
often concentrated around arterioles. The infarct scar size and myoblasts in the fibrin group
were significantly smaller than those in the control and BSA groups. Fibrin glue also
significantly increased the arteriole density in the infarct scar as compared with the control
group.
CONCLUSIONS This study indicates that fibrin glue increases cell transplant survival, decreases infarct size,
and increases blood flow to ischemic myocardium. Therefore, fibrin glue may have potential
as a biomaterial scaffold to improve cellular cardiomyoplasty treat and MIs. (J Am Coll
Cardiol 2004;44:654–60) © 2004 by the American College of Cardiology Foundationp
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teart failure following a myocardial infarction (MI) is often
rogressive. Scar tissue formation and aneurysmal thinning
f the infarct region often occur in patients who survive
Is, leading to congestive heart failure. Currently, heart
ransplantation is the only successful treatment for end-
tage heart failure; however, the ability to provide this
reatment is limited by the availability of donor hearts.
Cellular cardiomyoplasty involves the transplantation of
iable cells to replace the necrotic cardiomyocytes. Several
roups have examined delivering a variety of cell types,
ncluding skeletal myoblasts, fetal and neonatal cardiomyo-
ytes, and embryonic and adult stem cells to the ischemic
yocardium (1–11). The current transplantation technique
nvolves the injection of cells afloat in saline, cell culture
edium, or bovine serum albumin (BSA) and results in
iable grafts; however, the technique is plagued by limited
ell retention and transplant survival (5,8,11,12). It was
ecently stated that the “basic protocol for cell grafting may
eed further optimization to prevent cell loss” (12).
The emerging field of tissue engineering may provide
romising alternatives. Tissue-engineering approaches are
esigned to repair lost or damaged tissue through the use of
ellular transplantation and biomaterial scaffolds. Other
roups have used this tissue-engineering approach by im-
From the *University of California Berkeley and San Francisco Joint Bioengineer-
ng Graduate Group, †Department of Medicine, and ‡Cardiovascular Research
nstitute, University of California San Francisco, San Francisco, California. This
esearch was supported by a grant from the Nora Eccles Treadwell Foundation.
Manuscript received December 2, 2003; revised manuscript received March 22,
A004, accepted April 13, 2004.lanting cells on the surface of the myocardium in a polymer
caffold (13,14); however, this approach does not deliver
iable cells into the infarct wall. Moreover, there is a limit
n the thickness of these cultured implants due to lack of
ascularization.
In this study, we examine a novel approach to heart repair
hat uses an injectable biopolymeric scaffold to deliver cells
irectly into the infarct wall. We hypothesized that the
njection of cells in a solution that becomes a semi-rigid
caffold upon injection would increase cell transplant reten-
ion and survival within the infarct, compared with the
tandard injection technique. The bioactive fibrin scaffold is
lso known to be angiogenic (15–18), and we examined
hether this material could promote angiogenesis and
rteriogenesis in ischemic myocardium. We have previously
eported that the injection of fibrin glue preserves cardiac
unction and wall thickness after acute ischemic myocardial
njury (19). In this study, we further examined fibrin glue’s
ffect on left ventricle (LV) remodeling by examining its
ffect on infarct size. These hypotheses were tested using a
at acute MI and allograft transplantation model.
ETHODS
his study was approved by the Committee for Animal
esearch of the University of California San Francisco and
as performed in accordance with the recommendations of
he American Association for Accreditation of Laboratory
nimal Care (Rockville, Maryland).
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August 4, 2004:654–60 Fibrin Scaffold Improves Cell Transplant Survivalat MI model. A previously described ischemia reperfu-
ion model was used in this study (20). Briefly, female
prague-Dawley rats (225 to 250 g) were anesthetized with
etamine (90 mg/kg) and xylazine (10 mg/kg). Under sterile
echnique, the rats were placed in a supine position and the
hests were cleaned and shaved. The chests were then
pened by performing a median sternotomy, and the peri-
ardial sacs were removed. While the landmarks of the base
f the left atrium and the interventricular groove were kept
n view, a single stitch of 7-O Ticron (U.S. Surgical,
orwalk, Connecticut) suture was placed through the myo-
ardium at a depth slightly greater than the perceived level
f the left coronary artery, taking care not to enter the
entricular chamber. The suture was tightened to occlude
he artery for 17 min and then removed to allow for
eperfusion. The chest was then closed, and the animal was
llowed to recover for one week. This laboratory has
xtensive experience with this model and has previously
emonstrated that this technique results in an acute infarct
ize of approximately 30% of the LV with reperfusion
21–23).
keletal myoblast isolation and culture. Myoblasts from
he hind limb muscle of one litter of Sprague-Dawley neonatal
ats (10 to 12 rats; 2 to 5 days old) were isolated and purified
ccording to the following described procedure (24). Briefly,
he hind limb was harvested under phosphate-buffered saline
PBS)-penicillin/streptomycin and mechanically minced. The
issue was enzymatically dissociated with dispase and collage-
ase (Worthington, Lakewood, New Jersey) in Dulbecco’s
BS (Sigma Chemical Co., St. Louis, Missouri) for 45 min at
7°C. The resulting suspension was then passed through an
0-m filter, and the cells that passed through the filter were
ollected by centrifugation. The cells were preplated for 10 min
o isolate myoblasts from fibroblasts since fibroblasts plate
uicker than myoblasts. The myoblast suspension was trans-
erred to a collagen-coated 100-mm polystyrene tissue culture
ish and allowed to proliferate in growth media (80% Ham’s
10C media, 20% fetal bovine serum, 1% penicillin/
treptomycin, 2.5 ng/ml recombinant human basic fibroblast
rowth factor) at 37°C in a humidified atmosphere of 95% air
lus 5% CO2. Cultures were allowed to reach a confluency of
0% to 75% and passaged every three to four days (1:4 split).
ultures were examined for fibroblast contamination, and only
opulations of 95% myoblasts were acceptable for injection.
o verify the percentage of myoblasts in the population,
ultured cells were stained with desmin (Sigma; 1:20 dilution)
Abbreviations and Acronyms
BSA  bovine serum albumin
DAPI  4,6-diamidino-2-phenylindole
LV  left ventricle
MHC  myosin heavy chain
MI  myocardial infarction
PBS  phosphate-buffered salineo label myoblasts and Hoechst 33342 (Molecular Probes, Nugene, Oregon) to label nuclei. Rat fibroblasts (American
ype Culture Collection, Rockville, Minnesota) and L6 rat
yoblasts (American Type Culture Collection) were also
tained as negative and positive controls, respectively (Fig. 1).
ll injections were from the same pool of cells. Prior to
njecting the rats, which were sacrificed 24 h after injection, the
yoblasts were labeled with 4,6-diamidino-2-phenylindole
DAPI) for 25 min (3 M; Molecular Probes).
ibrin glue. The fibrin glue used in this study was the
ommercially available Tisseel VH fibrin sealant (Baxter
ealthcare Corp., Glendale, California). It is a two-
omponent system that remains liquid for several seconds
efore solidifying into a solid gel matrix. The first compo-
ent consists of concentrated fibrinogen and aprotinin, a
brinolysis inhibitor. The second is a mixture of thrombin
nd CaCl2. It is delivered through the supplied Duploject
pplicator, which holds the two components in separate
yringes and provides simultaneous mixing and delivery.
he ratio of fibrinogen to thrombin components was 1:1.
n vitro cell survival in fibrin glue. To determine whether
keletal myoblasts were capable of surviving in fibrin glue,
5 l of the thrombin solution containing 2  105 myo-
lasts per microliter was combined with 75 l of fibrinogen
olution and plated onto four-well chamber slides (1.7-cm2)
ishes. Growth media were added to the dishes and
hanged every three days. At one day, three days, and seven
ays in culture, a Live/Dead stain (Molecular Probes) was
sed to label live and dead cells. Each culture time point was
erformed in duplicate. Five microliters of 2 mM ethidium
omodimer-1 solution and 1.25 l of 4 mM calcein was
dded to 10 ml of PBS. Each chamber was incubated with
00 l of this solution for 30 min. The myoblast-fibrin glue
ultures were then rinsed with PBS and examined using a
igure 1. Transplant myoblasts. (A) Phase contrast images. (B) Desmin-
abeled cells. (C) Hoechst 33342-labeled nuclei. Transplant rat myoblasts
bottom panel) were stained with desmin and hoechst to verify myoblast
ercentage. Desmin staining indicates that cultured cell populations, which
ere subsequently injected into the myocardium, contained 95% myo-
lasts. One contaminating fibroblast is indicated by the arrows. Control rat
broblasts and rat myoblasts from the L6 cell line were stained with desmin
nd hoechst as negative and positive controls, respectively.ikon TE 300 fluorescent microscope (Nikon, Melville,
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Fibrin Scaffold Improves Cell Transplant Survival August 4, 2004:654–60ew York) for the presence of both surviving and non-
urviving cells.
njection surgeries. One week after MI, either 0.5% BSA
n 50 l of PBS, 50 l of fibrin glue, 5  106 myoblasts in
0 l of 0.5% BSA, or 5  106 myoblasts in 50 l of fibrin
lue was injected into the infarcted myocardium. Under
terile technique, the rats were anesthetized, and the abdo-
ens were opened from the xiphoid process to a left
ubaxillar level along the lower rib. The LV apex was
xposed via a subdiaphragmatic incision, leaving the chest
all and sternum intact. Rats were randomized to either
ontrol or treatment groups, and injections were made
hrough a 30-gauge needle into the infarcted area of the LV.
he ischemic area was identified by a darker region of the
V that has limited contractility. Injections were made at an
ngle to reduce the likelihood of injecting into the lumen of
he LV. Injections were verified by a slight lightening in
olor of the myocardium as the solutions entered the infarct
all. Injections were successful in each animal. One injec-
ion with a volume of 50 l was performed on each animal.
n the cells group, 5  106 myoblasts were suspended in 50
l of 0.5% BSA and injected into the myocardium. In the
ells in fibrin group, 5  106 myoblasts were suspended in
5 l of the thrombin component of the fibrin glue. The
hrombin-cell mixture was simultaneously injected into the
yocardium with 25 l of the fibrinogen component via the
axter’s supplied Duploject applicator, which provides si-
ultaneous mixing and delivery. Twenty-five microliters of
hrombin and 25 l of fibrinogen were simultaneously
njected into ischemic myocardium in the fibrin group. The
iaphragm was sutured closed after suction of the chest
avity, and the abdomen was subsequently closed.
istology. Either 24 h or 5 weeks after the injection
urgeries, the rats were euthanized with a pentobarbital
verdose (200 mg/kg). The study was concluded six weeks
fter infarction, at which point the remodeling process in
ats is complete (25). The hearts were rapidly excised and
resh frozen in Tissue Tek O.C.T. freezing medium
Sakura, Torrance, California). They were then sectioned
nto 5-m slices and stained with hematoxylin and eosin.
ive slides, equally distributed through the infarct area, were
aken from each heart as a representative sample and
easured for infarct size as previously described (26).
riefly, the infarct and LV were traced, and size was
etermined using planimetry. Infarct scar size was deter-
ined as the infarct scar area divided by the total LV area
s measured with SPOT 3.5.1 software (Diagnostic Instru-
ents, Sterling Heights, Michigan) and recorded as a
ercentage of the LV. Five additional slides from both the
4-h cells in BSA group (n  5) and 24-h cells in fibrin
roup (n  4) were examined for presence of DAPI-labeled
ransplanted cells. To measure cell retention within the
yocardium, the area covered by the DAPI-labeled myo-
lasts was traced using SPOT 3.5.1 (Diagnostic Instrument
nc., Sterling Heights, Michigan) according to a previously
escribed procedure, which used an orange cell tracker mather than DAPI (11), and was expressed as percentage of
he infarct area. All hematoxylin and eosin stained slides
lso were examined for any evidence of an immune reaction
y our cardiac pathologist.
mmunohistochemistry. Five slides, equally distributed
hrough the infarct area, were also taken from each heart in
he five-week BSA group (n  6), five-week fibrin group (n
5), five-week myoblasts in BSA group (n  5), and
ve-week myoblast in fibrin group and stained with an
nti-smooth muscle actin antibody (Dako; 1:75 dilution) to
abel microvessels that are predominately arterioles (27).
ive slides also were taken from each heart in the five-week
yoblasts group (n  5) and five-week myoblasts in fibrin
roup (n  5) after sacrifice and stained with the MY-32
lone (Sigma; 1:400 dilution), which is directed against the
keletal fast isoform of myosin heavy chain (MHC) (28), in
rder to label transplanted cells. Sections of rat hind limb
keletal muscle also were stained with the anti-skeletal
HC antibody to serve as a positive control. Sections that
ere incubated only with the secondary antibody were used
s negative controls. Slides were initially fixed in 1.5%
ormaldehyde and then blocked with staining buffer (0.3%
riton X-100 and 2% normal goat serum in PBS). Sections
ere incubated with the primary antibody diluted in stain-
ng buffer. In order to visualize labeled arterioles and skeletal
yoblasts, sections were incubated with a Cy-3-conjugated
nti-mouse secondary antibody (Sigma; 1:100 dilution).
ections were mounted with Gel/Mount (Biomeda).
lpha-smooth muscle actin labeled microvessels in each
ection were quantified using the following criteria: 1)
ositive for smooth muscle labeling; 2) within or bordering
he infarct scar; 3) having a visible lumen; and 4) having a
iameter between 10 and 100 m. The scar area was
easured using SPOT 3.5.1 software, and arteriole densi-
ies were calculated. Cell survival was determined according
o a previously described procedure (29) by measuring the
rea covered by cells that stained positive for anti-skeletal
ast MHC using Scion Image (Scion, Frederick, Maryland).
ell area was reported as percentage of infarct area. This
ethod of determining cell survival addresses the amount of
ransplant cells surviving in the myocardium and does not
ecessarily determine those transplant cells that have un-
ergone engraftment. Five additional slides were taken from
ach heart in all of the five-week groups. Capillaries were
abeled using a previously described procedure (14). Slides
ere fixed in room-temperature acetone, and endogenous
eroxide activity was quenched with 3% H2O2. Sections
ere incubated with biotinylated Griffonia simplicifolia
ectin (GSL-1; Vector Labs; Burlingame, California). Sec-
ions were then incubated with peroxidase-conjugated
treptavidin (LSAB2 System, HRP, DakoCytomation,
lostrup, Denmark), capillaries were visualized using 3,3-
iaminobenzidine chromagen solution (LSAB2 System),
nd sections were mounted with Gel/Mount. Five high-
agnification fields within the infarct of each section were
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August 4, 2004:654–60 Fibrin Scaffold Improves Cell Transplant Survivalhosen at random, capillaries were counted, and vessel
ensity was calculated.
tatistical analysis. Data are presented as mean  stan-
ard deviation. Cell density measurements were compared
sing the student t test. Infarct size and vessel measure-
ents were compared using one-way analysis of variance
ith Holm’s adjustment. Significance was accepted at p 
.05.
ESULTS
total of 43 rats were used in this study. Eight rats died
uring or immediately after the infarct surgery, whereas one
at died during the injection surgery (cells in fibrin glue
roup). After the injection surgery, there was 100% survival
n all groups.
n vitro cell survival in fibrin glue. Myoblasts were
apable of surviving and proliferating in fibrin glue up to
even days in culture. There was little, if any, cell death
aused by the matrix (Fig. 2). Myoblasts had greatly
roliferated and were at a high density within the matrix
fter culture for seven days in growth media.
ell retention and survival. After 24 h, myoblast densities
n BSA and fibrin glue after injection were not significantly
ifferent (p  0.85). Myoblasts injected in BSA comprised
5.8  9.2% of the infarct, whereas myoblasts injected in
brin glue covered 17.3 14.6%. Myoblasts transplanted in
brin glue were found both in clumps surrounded by the
brin matrix and dispersed within its fibrils (Fig. 3). After
ve weeks, the myoblast density in the infarct area was
ignificantly greater when the cells were injected in the
brin glue than when injected in BSA (p  0.03). Cells
njected in fibrin glue covered 9.7 4.2% of the infarct area
ompared with 4.3  1.5% when injected in BSA. Trans-
lanted myoblasts injected in BSA were most often found at
igure 2. Myoblast survival in fibrin glue in vitro (4). (A) Surviving
yoblasts after three days in culture in fibrin glue. (B) Surviving myoblasts
fter seven days in culture in fibrin glue. (C) Dead myoblasts after three
ays in culture in fibrin glue. (D) Dead myoblasts after seven days in
ulture in fibrin glue. Note the small amount of death as a result of the
urrounding matrix.he border of the infarct scar and not within the ischemic aissue at five weeks after injection (Figs. 4A and 4C). In
ontrast, myoblasts injected in fibrin glue were found both
t the border and within the infarct scar (Figs. 4B and 4D).
ells transplanted in fibrin glue were often surrounding
rterioles within the infarct scar (Figs. 4B and 4D, arrow-
eads). Figures 4C and 4D display the location of the
ormal and infarcted myocardium, thus allowing one to
igure 3. Myoblast in fibrin glue 24 h after injection. (A) 4,6-diamidino-
-phenylindole-labeled myoblasts (4) injected in fibrin glue are found in
he infarct wall. (B) Corresponding hematoxylin and eosin stained section
4). Transplanted myoblasts are surrounded by fibrin glue within the
nfarct scar. (C) Higher-magnification hematoxylin and eosin section
10) displaying transplanted myoblasts in fibrin glue. (D) Hematoxylin
nd eosin stained section (10) of fibrin glue ex vivo.
igure 4. Myoblast survival and location within myocardium after five
eeks (100). (A and B) Anti-skeletal, fast myosin heavy chain-labeled
yoblasts visualized with a Cy3 secondary antibody. (C and D) Hema-
oxylin and eosin-stained sections that neighbor (A) and (B), respectively.
C and D) Normal and infarcted myocardium are labeled to visualize the
ocation of transplanted cells. (A) Transplanted skeletal myoblasts in
ovine serum albumin are located at the border of the infarct scar. (B) In
ontrast, a greater number of skeletal myoblasts injected in fibrin glue are
ocated both at the border and within the infarct scar. Surviving myoblasts
re in clumps surrounding arterioles (arrows in B and D) in the scar.
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Fibrin Scaffold Improves Cell Transplant Survival August 4, 2004:654–60isualize the location of the anti-skeletal, fast MHC labeled
yoblasts in Figures 4A and 4B, respectively.
istology. Infarct scar size as determined by percent of the
V was measured for each group. The infarct size in the
ontrol (BSA) group was 26.5  2.2%. There was no
ignificant difference in infarct size between the three
reatment groups (p  0.45); however, both injection of
brin glue and myoblasts in fibrin glue resulted in signifi-
antly smaller infarcts (p  0.03 and p  0.003, respec-
ively) compared with a BSA control injection. Fibrin glue
educed the infarct size to 19.7  3.8%, whereas myoblasts
n fibrin glue reduced the size to 17.5  3.4%. In contrast,
yoblasts injected in BSA did not produce a statistically
maller infarct than injection of BSA (20.9  5.2%; p 
.24) (Fig. 5). A histological review of hematoxylin and
osin stained sections from each group demonstrated that
here were no significant immune reactions. The scars did
ontain scattered hemosiderin-laden macrophages, which
re evidence of previous hemorrhage, and rare mononuclear
ells; however, there was virtually no active inflammation.
eovasculature formation. To assess the angiogenic poten-
ial of fibrin glue in ischemic myocardium, infarcted rat hearts
njected with fibrin glue and BSA were examined for capillary
ensity at five weeks after injection. There was no significant
ifference between groups (p  0.64). Microvessels were
abeled with anti-smooth muscle actin in both the fibrin and
SA groups to determine whether fibrin glue induces forma-
ion of larger vessels. Even without treatment, collateral arte-
ioles are often seen bordering the scar after MI; thus, separate
essel counts were performed on vessels within the infarct and
hose bordering the scar. Microvessel density data are summa-
ized in Table 1. Alpha-smooth muscle actin labeled microves-
el density for the total infarct area in the fibrin group was
ignificantly greater than that in the BSA group (p  0.004).
here was no difference in vessel density bordering the infarct
etween the two groups (p  0.32); however, there was a
ignificant difference within the scar between the fibrin and
igure 5. Infarct size. The injection of fibrin glue and skeletal myoblasts
esulted in statistically smaller infarcts than injection of bovine serum
lbumin (BSA). In contrast, the infarct size of hearts injected with skeletal
yoblasts in BSA was not statistically different from hearts injected with
SA. *p  0.05 compared with BSA (fibrin, p  0.03; myoblasts in fibrin,
 0.003). LV  left ventricle.SA groups (p  0.001). The alpha-smooth muscle actin aabeled microvessel density of the two groups, including myo-
lasts, was also calculated. Injection of myoblasts in fibrin glue
ignificantly increased the total and within-scar microvessel
ensity compared with injection of myoblasts in BSA (p 
.007 and p  0.02, respectively). There was again no
ifference in alpha-smooth muscle actin labeled microvessels
ordering the infarct scar (p  0.21). We also compared the
SA group with the myoblasts in BSA group and the fibrin
roup with the myoblasts in fibrin group to determine whether
he addition of myoblasts affected microvessel formation. The
ddition of myoblasts in both BSA and fibrin resulted in a
ignificant or near-significant decrease in the total vessel
ensity (p 0.04 and p 0.05, respectively). The addition of
yoblasts also decreased the within-scar vessel density (p 
.02 and p  0.01, respectively). After the injection of fibrin
lue, a large number of alpha-smooth muscle actin labeled
icrovessels, predominately arterioles, were found within the
nfarct scar (Figs. 6A and 6B). Figure 6B has been stained with
ematoxylin and eosin and is the neighboring slide to Figure
A. Normal, healthy myocardium, which is denoted by its
arker staining, and the infarct scar, which is denoted by
ighter staining, can both be visualized in Figure 6B. Figure 6B
emonstrates that the large number of labeled arterioles in
igure 6A are in fact within the infarct scar.
ISCUSSION
ur results indicate that cell transplant survival, but not cell
etention, in infarcted myocardium is enhanced by injection of
ells in fibrin glue. Injection of cells in fibrin glue did not affect
he amount of myoblasts in the infarct after 24 h. These results
able 1. Microvessel Data
Arterioles/mm2 Total
Within
Infarct
Border
Zone
SA 10  2 10  2 3  1
ibrin 16  1 13  1 3  0
values (BSA vs. fibrin) 0.004 0.001 0.32
yoblasts in BSA 6  2 4  2 2  1
yoblasts in fibrin 13  3 9  2 4  1
values (myoblasts in BSA vs.
myoblasts in fibrin)
0.007 0.02 0.21
SA  bovine serum albumin.
igure 6. Fibrin-induced arteriole formation (100). (A) Anti-smooth
uscle actin-labeled arterioles visualized with a Cy3 secondary antibody.
B) Hematoxylin and eosin stained section that neighbors (A). (B) Normal,
ealthy myocardium is denoted by the darker staining whereas the infarct
car has lighter staining. (A and B) Fibrin induces the formation of several
rterioles within the infarct.
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August 4, 2004:654–60 Fibrin Scaffold Improves Cell Transplant Survivalndicate that fibrin glue does not increase cell retention.
ecause fibrin glue remains liquid for a few seconds, cells may
ontinue to be squeezed out of the beating myocardium upon
njection. In contrast, the area of the infarct wall covered by
ransplanted myoblasts after five weeks was significantly greater
hen the myoblasts were injected in fibrin glue, indicating that
brin increases cell survival. Fibrin may increase cell survival by
cting as a temporary extracellular matrix for the transplanted
ells. Typically, cells are injected in completely liquid formu-
ations of saline, cell culture medium, or BSA; however, fibrin
lue solidifies inside the myocardium, giving the cells a
emporary semi-rigid scaffold. Fibrin glue also contains
rginine-glycine-asparagine (RGD) motifs and binds to cell
eceptors (predominately integrins) (30). Upon injection in
brin glue, the cells are entrapped within this temporary
xtracellular matrix. A previous study has demonstrated that
he fibrin matrix is maintained for 7 to 10 days before
egradation (31), thus allowing time for the transplanted cells
o form their own matrix. Fibrin glue is thus an injectable
caffold that promotes viability of cells delivered directly into
he infarct wall. Another possibility for the increase in cell
urvival is that the injection of fibrin glue into ischemic
yocardium induced neovasculature formation. An increase in
lood supply would provide a less ischemic region for the cells
o thrive. It has been previously reported that the injection of
ells into vascularized myocardium increases survival compared
ith injection in ischemic myocardium (11). This is further
upported by the observation that myoblasts injected in fibrin
lue were often found surrounding arterioles within the infarct
car. By increasing cell transplant survival in ischemic myocar-
ium, fibrin glue may be the necessary modification to the
tandard transplantation procedure. There is also the possibility
hat the fibrin matrix induces myoblast proliferation, which
ould increase the number of surviving cells in the myocar-
ium.
We have also demonstrated that injection of fibrin glue
lone as well as myoblasts in fibrin glue decreases infarct scar
ize. A decrease in the area covered by the scar indicates a
eduction of late infarct expansion. As an indicator of
egative LV remodeling, a decrease in late infarct expansion
ndicates that fibrin is capable of preventing negative LV
emodeling after MI in rats. These histological results
orroborate initial echocardiographic findings, which dem-
nstrated that fibrin glue and cells in fibrin glue preserved
all thickness and fractional shortening (19). Fibrin may
erve as an internal wall support by increasing stiffness. It
ay also simply affect remodeling by increasing wall thick-
ess. Although there was no significant difference in infarct
ize among the three treatment groups, injection of skeletal
yoblasts in BSA did not produce a statistically smaller
nfarct than the control injection, consistent with previous
eports of transplantation survival problems within infarcted
yocardium (5,8,11,12). This trend indicates that fibrin
nd myoblasts in fibrin glue may have the potential to
roduce smaller infarcts than injection of myoblasts in BSA. fhe injection of myoblasts in BSA may not be capable of
roducing a large enough graft to reduce infarct size.
Fibrin glue also induced alpha-smooth muscle actin
abeled microvessel formation within the infarct scar, thus
uggesting an increase in blood supply to the ischemic
yocardium. Although larger alpha-smooth muscle actin
abeled microvessels may be venules, the majority of vessels
ould be arterioles. It is significant that fibrin glue results in
rteriogenesis since formation of solely capillaries does not
ecessarily indicate an increase in blood flow, due to the ease
f regression of vessels without smooth muscle (32). Fibrin
id not, however, increase capillary formation compared
ith the injection of BSA. Injection into the myocardium is
nown to induce some angiogenesis. Fibrin may therefore
ot be capable of producing a greater angiogenic response.
n addition, the increase in larger vessels may be a result of
he differentiation of existent capillaries into larger-diameter
rterioles. Natively, fibrin is highly involved in wound
ealing and acts as the body’s natural matrix for angiogen-
sis. Endothelial cells migrate through the fibrin clot via
v3 integrin binding to arginine-glycine-asparagine motifs
n fibrin (33). The production of plasmin at the location of
igrating endothelial cells degrades the fibrin matrix. This
ecrease in fibrin density allows for capillary tube formation
34). As the cells migrate through the less dense fibrin, they
nteract with residues on the beta chain of fibrin via vascular
ndothelial cadherins and promote capillary morphogenesis
35). In addition to providing a matrix for endothelial cell
igration and capillary tube formation, fibrin also acts as a
ustained-release reservoir for several growth factors (36)
nd fibrinolytic enzymes (37). A degradation product of
brin, fibrin fragment E, also has been shown to induce
ngiogenesis in the chick chorioallantoic membrane assay
15), and stimulate proliferation, migration, and differenti-
tion of human microvascular endothelial cells (16), and
timulate migration and proliferation of smooth muscle cells
17). The administration of exogenous fibrin into the
ubcutaneous space of guinea pigs also has been shown to
nduce angiogenesis (18).
Fibrin glue is an already Food and Drug Administration-
pproved biomaterial that is routinely used as a surgical
dhesive and sealant. This biopolymer is formed by the
ddition of thrombin to fibrinogen. Thrombin enzymatically
leaves fibrinogen, which then forms the polymer fibrin. After
ombination of the two components, the solution remains
iquid for several seconds before polymerizing. Fibrin glue
ould therefore be delivered to the myocardium via catheter in
umans, thus requiring only a minimally invasive procedure;
owever, certain precautions must be taken to avoid injection
nto the LV cavity or coronary vessels, which could result in an
mbolic event. It is also biocompatible and non-toxic and does
ot induce inflammation, foreign body reactions, tissue necro-
is, or extensive fibrosis (38). Our laboratory has also demon-
trated that the injection of fibrin glue alone or skeletal
yoblasts in fibrin glue prevents the deterioration of cardiacunction and infarct wall thinning after MI in rats (19).
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yoblasts, we anticipate that fibrin glue would improve cell
iability of other transplanted cells such as stem cells.
tudy limitations. One limitation of the animals used in this
tudy is that they were not an inbred strain and an allograft
ransplantation was performed; thus, graft rejection is expected
o be higher. Our preliminary results with fibrin glue and
yoblasts indicated that viable grafts survive in Sprague-
awley rats. Sprague-Dawley rats represent a “worst-case”
cenario for cell survival because of their increased immune
eaction. If fibrin glue is capable of increasing graft size in this
worst-case” scenario, we anticipate that we would find a more
ramatic effect in an inbred strain.
onclusions. This study indicates that fibrin glue may have
otential in the treatment of patients suffering from MI. It may
e a possible treatment that increases neovasculature formation
nd decreases infarct size or a possible novel method for
ncreasing cell transplant graft size in ischemic myocardium.
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